An in vivo base editing approach targeting the PRNP gene led to a 52% increase in the lifespan of mouse models inoculated with the most common sporadic and genetic types of human pathogenic prion ...

The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and ...

Starbird, the 1997 Naismith Player of the Year, was excited to play in her hometown for Seattle's ABL franchise. To seal the deal, the ABL offered her a contract that according to reports at the ...

In CML, blast cells (or immature white blood cells) form and uncontrollably multiply and divide. This change in cells creates an abnormal gene called BCR-ABL, which is responsible for turning healthy ...

The first human trial of insulin-producing cells that have been gene-edited to evade immune attack is a success so far. The cells have survived and produced insulin for a month after being ...

National firm ABL 1 Touch has been announced as the tenant of the first unit constructed within the £200million Business Park South development, marking a milestone in the park’s growth.

The Alliance for Regenerative Medicine’s (ARM) Cell & Gene Meeting on the Med, took place in Barcelona back in April. ABL Biomanufacturing - a pure play Contract Development and Manufacturing ...

This complex process, known as gene expression, determines which proteins we make and whether we make them in the correct amounts, crucial work given that proteins play a role in virtually every a ...

A ba­by boy born with a de­bil­i­tat­ing ge­net­ic dis­ease will like­ly no longer re­quire a liv­er trans­plant to sta­bi­lize his con­di­tion, thanks to a first … ...

Summary: Researchers have developed an AI model that accurately predicts gene activity in any human cell, providing insights into cellular functions and disease mechanisms. Trained on data from over 1 ...

The same is now possible in gene editing. Rather than employ separate tools for editing genes and regulating their expression, these distinct goals can now be combined into a single tool that can ...

ELVN-001 targets the BCR-ABL gene fusion, addressing resistance issues seen with other TKIs, including the T315I mutation. Financially, Enliven has a market cap of $1.9bn and a cash runway of 7 ...